Updated
Updated · POLITICO · Jul 14
HHS, VA Sign Psychedelic-Trial Pact for Veterans as FDA Fast-Tracks 3 Drugs
Updated
Updated · POLITICO · Jul 14

HHS, VA Sign Psychedelic-Trial Pact for Veterans as FDA Fast-Tracks 3 Drugs

3 articles · Updated · POLITICO · Jul 14

Summary

  • HHS and the VA signed a memorandum on Monday to coordinate clinical trials of psychedelic drugs aimed at improving veterans’ mental health under Trump’s April executive order.
  • The pact sets up data sharing, therapist and clinician training, clinical protocols and preparation across the VA system so future FDA-approved psychiatric treatments can be implemented quickly.
  • FDA has already fast-tracked three psychedelic drugs for review, finalized guidance on psychedelic drug development and scheduled a public hearing in September on therapeutic uses.
  • The move follows frustration from psychedelic advocates over Robert F. Kennedy Jr.’s earlier lack of action, and marks a broader federal push to speed treatment options for serious mental illness.

Insights

As federal agencies fast-track psychedelic therapies, what key challenges remain before they reach the public?
As the US cracks down on medical fraud, how will the record billions in savings impact patient costs?
Amidst GLP-1 popularity, how effective are new programs at ensuring safe and affordable access for patients?